Evotec has been a leader in drug discovery and development for over 30 years, offering end-to-end solutions from target identification to clinical trials. Their innovative approach leverages deep disease understanding, cutting-edge technologies, and tailored solutions, supporting collaborations through standalone services, integrated programs, or strategic partnerships to create impactful medicines. | Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure, faster, smarter, and with greater precision. At the heart of our innovation are proprietary platforms including Molecular Patient Databases, PanOmics, and iPSC-based disease modeling, which uniquely support our expertise in small molecules, biologics, cell therapies, and other key modalities. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
EnquBio
EnquBio is a San Diego-based preclinical CRO built for the complexity of modern drug discovery. We offer an integrated suite of capabilities including biological tissue models, orthotopic in vivo oncology models, iPSC platforms, in vitro pharmacology, and a comprehensive Immunology & Biomarkers platform spanning flow cytometry, MSD multiplex, and protein quantification designed to deliver biologically meaningful, translatable data at every stage of preclinical development. Whether you’re profiling tumor microenvironment biology, evaluating checkpoint inhibitors, advancing ADCs or bispecifics, or characterizing fibrotic or inflammatory disease, EnquBio brings the scientific rigor and platform depth to answer your most critical research questions. We don’t just run assays, we partner with your team to design studies that generate the kind of clean, reproducible, AI-ready data that accelerates decision-making and de-risks your pipeline.
Encompass Pharmaceutical Services, Inc.
Encompass Ophthalmic Development Services, Inc. offers a full range of ophthalmic development and formulation services from pre-formulation through manufacturing scale-up. • Preclinical Support • Consulting • Ophthalmic Drug Formulation • Ophthalmic Drug Delivery • Ex-vivo drug release characterization • Analytical Method Development and Validation • Pre-Clinical Supplies Manufacturing • Manufacturing Process Development, Scale-up, and Validation • GMP Stability Studies • Clinical Supplies and Manufacturing Support
Enamine
Enamine is a global provider of Screening Compounds (small molecules), Building Blocks, Fragments, HTS/AMDE/PK services, and custom synthesis for supporting a wide range of research programs conducted by pharmaceutical and biotech companies, drug discovery centres, academic institutions and other research organizations worldwide. Enamine offers a broad range of targeted libraries covering many of the most important cancer targets. These libraries have been designed using diverse computational approaches and algorithms by Enamine’s CADD team, as well as through collaborations with industry partners and academic groups.
Emergent CRO
Emergent CRO is a MedTech-focused clinical research organization supporting orthopedic, spine, and sports medicine innovators from first-in-human through post-market. We deliver senior-level oversight, agile execution, and transparent pricing. Acting as an extension of your team, we integrate seamlessly to design smarter studies, activate the right sites, and keep trials moving forward. We don’t just manage studies, we become true partners in your success. Built to Care. Built for MedTech!
EMD Serono
EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, is a science-led organization dedicated to making a meaningful difference in the lives of people affected by cancer. Our oncology research aims to leverage our synergistic portfolio to tackle challenging tumor types, as we work to illuminate a path to scientific breakthroughs to transform patient outcomes. Learn more at www.emdseronooncology.com | We are the healthcare business in the U.S.A. & Canada for Merck KGaA, Darmstadt, Germany, a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people’s lives every day. In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information. Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live. We are curious minds dedicated to human progress. | In Healthcare, we are at the forefront of developing pioneering therapies – boldly aiming to meaningfully change the lives of patients, their families, and their caregivers. We are unlocking leaps in highly specialized fields with significant unmet medical needs. We leverage internal discoveries and external partnerships to serve patients who need it most across all continents. As one company, science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people’s lives every day. Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information. Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live. We are sparking discovery, elevating humanity. | We are the healthcare business in the U.S.A. & Canada for Merck KGaA, Darmstadt, Germany, a vibrant science and technology company. EMD Serono Aspires to create, improve and prolong lives — As One for Patients. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people’s lives every day. In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information. Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live. We are curious minds dedicated to human progress.
Elsevier
As a global leader in information and analytics, we help researchers and healthcare professionals to advance science and improve health outcomes, striving to create a better future for everyone. We offer evidence-based information and advanced AI solutions to support the work of the research and healthcare communities worldwide. | A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies. | Elsevier Health applies innovation, facilitates insights, and helps drive more informed decision-making for students, clinicians, leaders, educators and policymakers, across healthcare systems globally. We support health providers by supplying accessible, trusted evidence-based information to take on the infodemic; preparing more future health professionals; improving patient outcomes; delivering truly inclusive healthcare; and supporting personalized and localized care experiences. Together, we aim to empower healthcare professionals to provide optimal care that improves outcomes for all patients. | A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies. We have supported the work of our research and healthcare communities for more than 140 years. Our 9,700 employees around the world, including 2,300 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 3,000 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy. Together with the Elsevier Foundation, we work in partnership with the communities we serve to advance inclusion in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com. | For more than 140 years, Elsevier has helped advance science and human progress. We’ve evolved to a global leader in seamlessly integrating trusted content, technology and scientific expertise to support research and development. Discover, innovate and develop with confidence supported by a portfolio of connected, configurable solutions for R&D. | Elsevier, a global leader in information and analytics, helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. Growing from our roots in publishing, we have supported the work of our research and health partners for more than 140 years. Powered by responsible AI, ClinicalKey AI is a clinical decision support solution that delivers relevant insights at the point of care sourced from trusted, evidence-based content.
Eli Lilly and Company
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom. | Lilly unites caring with discovery to create medicines that improve lives for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today, our medicines help more than 51 million people worldwide. We’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter, and LinkedIn. | Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people.